Larvol Delta - Blue-Earth-Therapeutics-Awarded-UK-MHRA-Innovation-Passport-for-Investigational-177LurhPSMA101-for-Treatment-of-Metastatic-CastrateResistant-Prostate-Cancer-mCRPC

177Lu-rhPSMA-10.1 - Bracco

https://www.businesswire.com/news/home/20221108005107/en/Blue-Earth-Therapeutics-Awarded-UK-MHRA-Innovation-Passport-for-Investigational-177Lu-rhPSMA-10.1-for-Treatment-of-Metastatic-Castrate-Resistant-Prostate-Cancer-mCRPC

Nov 8, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next